摘要
目的观察补益脾肾方联合5-氟尿嘧啶(5-Fu)对荷瘤小鼠的抑瘤和免疫调节作用。方法建立H22肝癌荷瘤小鼠模型。随机分为4组:模型组、5-Fu组、补益脾肾方(高、低剂量)+5-Fu组,每组8只,造模次日开始治疗。模型组口服和腹腔注射等量生理盐水,5-Fu组腹腔注射5-Fu,补益脾肾方高、低剂量+5-Fu组口服补益脾肾方和腹腔注射5-Fu。用药10 d,停药次日处死小鼠,检测小鼠瘤质量、肿瘤抑制率、体质量、脾指数、脾脏NK细胞杀伤活性、T淋巴细胞增殖活性、T淋巴细胞亚群比例。结果补益脾肾方+5-Fu各组瘤质量明显低于5-Fu组和模型组(P<0.05);与模型组相比,5-Fu组体质量、脾指数、脾脏NK细胞杀伤活性、T淋巴细胞增殖活性、CD4/CD8值明显降低(P均<0.05),而联合治疗各组体质量、脾指数、脾脏NK细胞杀伤活性、T淋巴细胞增殖活性、CD4/CD8值明显升高(P均<0.05)。结论补益脾肾方与5-Fu合用可增强抑瘤作用,对氟尿嘧啶所致的免疫功能损伤具有保护作用。
Objective It is to observe the effects of tumor inhibiting and immunoloregulation of Buyipishen prescription combined with 5-fluorouracil(5-Fu) on tumor transplanted mice.Methods Hepatoma 22 bearing mice models were established and then randomly divided into four groups,including control group(fed orally and intraperitoneal injected with same amount of natural saline),5-Fu group(injected intraperitoneally with 5-Fu),Buyipishen prescription(high,low dose) plus 5-Fu groups(fed orally with Buyipishen prescription and injected intraperitoneally with 5-Fu).There were 8 mice in each group.After treat ment for 10 days,the mice were killed.The mass of body and tumor,tumor inhibiting rates,spleen gland indexes,the toxicity activity of splenic NK cells,the proliferation activity of T lymphocytes, and the value of CD4+/CD8+ were detected.Results The tumor inhibiting rates were higher in each Buyipishen prescription plus 5-Fu group than that in the 5-Fu group(P〈0.05).Compared with the control group,the spleen gland indexes,the toxicity activity of splenic NK cells,the proliferation activity of T lymphocytes,and the value of CD4+/CD8+ in 5-Fu group were lower(P〈0.05).But in the two Buyipishen prescription plus 5-Fu groups,they were higher(P〈0.05).Conclusion Buyipishen prescription can enhance the effect of anti-tumor efficacy of 5-Fu.It can also improve the immunological function and reduce the side-effect of chemotherapy.
出处
《现代中西医结合杂志》
CAS
2010年第3期269-271,共3页
Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词
补益脾肾方
5-氟尿嘧啶
抑瘤
免疫调节
Buyipishen prescription
5-Fluorouracil
tumor inhibition
immunoloregnlation